UK-based Oxford Biomedica Plc is to establish a gene therapy manufacturing presence in the US under a new agreement with Homology Medicines Inc, a clinical-stage genetics medicines company located near Boston, US. Homology has experience in the development and use of adeno-associated virus (AAV) vectors while Oxford Biomedica has a lentiviral vector delivery platform.
